The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study
Authors:
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 34 (3) , 107515
Abstract
No abstract availableKeywords
Funding Information
- China Medical University Hospital (DMR-108-027)
- Ministry of Health and Welfare, Taiwan (MOHW108-TDU-B-212-133004)
- China Medical University Hospital
- Academia Sinica (BM10701010021)
- MOST (MOHW108-TDU-B-212-133004)
- Tseng-Lien Lin Foundation
- Katsuzo and Kiyo Aoshima Memorial Funds
This publication has 28 references indexed in Scilit:
- Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance DatabaseBritish Journal of Dermatology, 2016
- Nationwide Population ScienceJAMA Internal Medicine, 2015
- Metformin induced bullous pemphigoid, the first caseInternational Journal of Scientific Reports, 2015
- Drug‐induced pemphigoid: a review of the literatureJournal of the European Academy of Dermatology and Venereology, 2014
- Pemphigoid diseasesThe Lancet, 2013
- Incidence and Mortality of Bullous Pemphigoid in FranceJournal of Investigative Dermatology, 2012
- Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based studyBritish Journal of Dermatology, 2011
- Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Case–Control StudyJournal of Investigative Dermatology, 2011
- The Association of Bullous Pemphigoid With Cerebrovascular Disease and DementiaArchives of Dermatology, 2010
- A Retrospective Epidemiological Study on the Association of Bullous Pemphigoid and Neurological DiseasesActa Dermato-Venereologica, 2005